Michael Kolinsky

2.0k total citations · 1 hit paper
54 papers, 824 citations indexed

About

Michael Kolinsky is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael Kolinsky has authored 54 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 17 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael Kolinsky's work include Prostate Cancer Treatment and Research (40 papers), PARP inhibition in cancer therapy (17 papers) and Radiopharmaceutical Chemistry and Applications (16 papers). Michael Kolinsky is often cited by papers focused on Prostate Cancer Treatment and Research (40 papers), PARP inhibition in cancer therapy (17 papers) and Radiopharmaceutical Chemistry and Applications (16 papers). Michael Kolinsky collaborates with scholars based in Canada, United Kingdom and United States. Michael Kolinsky's co-authors include Fred Saad, Neal D. Shore, Maha Hussain, Karim Fizazi, Bettina Noerby, Joyce Steinberg, Xun Lin, David F. Penson, Fabian Zohren and Cora N. Sternberg and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

Michael Kolinsky

50 papers receiving 817 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020 266 citations Fred Saad, Neal D. Shore et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Kolinsky Canada	13	572	361	197	182	168	54	824
Salvatore Luca Burgio Italy	16	594 1.0×	312 0.9×	246 1.2×	167 0.9×	268 1.6×	40	858
Hiroshi Haneda Japan	19	865 1.5×	531 1.5×	201 1.0×	346 1.9×	133 0.8×	62	1.3k
Francis Parnis Australia	14	457 0.8×	328 0.9×	160 0.8×	186 1.0×	88 0.5×	60	761
Zafeiris Zafeiriou United Kingdom	13	536 0.9×	422 1.2×	345 1.8×	158 0.9×	172 1.0×	31	873
Deborah Ricci United States	15	399 0.7×	474 1.3×	262 1.3×	261 1.4×	68 0.4×	51	876
Reyes Bernabé Spain	19	611 1.1×	684 1.9×	173 0.9×	211 1.2×	61 0.4×	92	1.1k
Guangxi Sun China	15	344 0.6×	190 0.5×	106 0.5×	156 0.9×	51 0.3×	84	614
Siobhan Ng Australia	12	360 0.6×	355 1.0×	77 0.4×	119 0.7×	169 1.0×	33	708
A. Kooistra Netherlands	12	576 1.0×	403 1.1×	198 1.0×	326 1.8×	95 0.6×	19	928
Ignacio Matos Spain	17	206 0.4×	521 1.4×	89 0.5×	195 1.1×	68 0.4×	57	818

Countries citing papers authored by Michael Kolinsky

Since Specialization

Citations

This map shows the geographic impact of Michael Kolinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kolinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kolinsky more than expected).

Fields of papers citing papers by Michael Kolinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kolinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kolinsky. The network helps show where Michael Kolinsky may publish in the future.

Co-authorship network of co-authors of Michael Kolinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kolinsky. A scholar is included among the top collaborators of Michael Kolinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kolinsky. Michael Kolinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Basappa, Naveen S., et al.. (2024). Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer. Current Oncology. 31(9). 5080–5087. 1 indexed citations

Cook, Sarah, Kosuke Takemura, Daniel Yick Chin Heng, et al.. (2024). Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer. 23(1). 102274–102274. 1 indexed citations

Kolinsky, Michael, et al.. (2024). A real-world observational study characterizing patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with or without androgen receptor pathway inhibitors (ARPIs).. Journal of Clinical Oncology. 42(4_suppl). 59–59. 1 indexed citations

Yip, Steven, Michael Kolinsky, Kosuke Takemura, et al.. (2023). 1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi). Annals of Oncology. 34. S972–S972. 1 indexed citations

Ye, Carrie, et al.. (2023). Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporosis International. 34(4). 735–740. 22 indexed citations

Zhang, Han‐Bo, Nimira Alimohamed, Naveen S. Basappa, et al.. (2023). High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors. Canadian Urological Association Journal. 18(3). E73–E79.

Kwan, Edmond M., Moira Rushton, Sébastien J. Hotte, et al.. (2023). Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.. Journal of Clinical Oncology. 41(6_suppl). 218–218. 4 indexed citations

Lee‐Ying, Richard M., Dylan E. O’Sullivan, Nimira Alimohamed, et al.. (2022). Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study. CMAJ Open. 10(3). E633–E642. 2 indexed citations

Kolinsky, Michael, Bryan Donnelly, Adrian Fairey, et al.. (2020). Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada. BMJ Open. 10(10). e037222–e037222. 9 indexed citations

10.

Romano, Emanuela, Srikala S. Sridhar, Michael Kolinsky, et al.. (2020). 620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update. Annals of Oncology. 31. S512–S513. 3 indexed citations

11.

Joshua, Anthony M., Howard Gurney, Margitta Retz, et al.. (2020). 217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study. Annals of Oncology. 31. S1325–S1325. 3 indexed citations

12.

Jiang, Di, Scott North, Christina Canil, et al.. (2020). Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. Bladder Cancer. 6(3). 363–392. 2 indexed citations

13.

Hotte, Sébastien J., Antonio Finelli, Kim N., et al.. (2020). Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal. 15(2). E90–E96. 4 indexed citations

14.

Yu, Evan Y., Josep M. Piulats, Gwénaëlle Gravis, et al.. (2020). 621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. Annals of Oncology. 31. S513–S514. 5 indexed citations

15.

Yu, Evan Y., Gwénaëlle Gravis, Brigitte Laguerre, et al.. (2020). Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.. Journal of Clinical Oncology. 38(15_suppl). 5544–5544. 8 indexed citations

16.

Warren, Mark, Michael Kolinsky, Christina M. Canil, et al.. (2019). Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal. 13(10). 318–327. 9 indexed citations

17.

Smylie, Michael, John Walker, Naveen S. Basappa, et al.. (2019). Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis. Clinical Rheumatology. 38(5). 1513–1519. 47 indexed citations

18.

Kolinsky, Michael, Nikolas H. Stoecklein, Maryou B. Lambros, et al.. (2019). Genetic Analysis of Circulating Tumour Cells. Recent results in cancer research. 215. 57–76. 11 indexed citations

19.

Lorente, David, Praful Ravi, Niven Mehra, et al.. (2016). Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus. 4(2). 235–244. 15 indexed citations

20.

Pond, Gregory R., Matthew I. Milowsky, Michael Kolinsky, et al.. (2014). Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. Clinical Genitourinary Cancer. 12(6). 440–446. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact